Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roivant Sciences Ltd.

11.03
-0.1400-1.25%
Post-market: 11.060.0300+0.27%17:18 EDT
Volume:5.80M
Turnover:64.32M
Market Cap:7.87B
PE:-70.86
High:11.25
Open:11.16
Low:10.90
Close:11.17
Loading ...

How Elon Musk and Vivek Ramaswamy teamed up to gut $2 trillion of government spending

Dow Jones
·
16 Dec 2024

Roivant Sciences Shares Down 3% as Co to Stop Lung Disease Drug Development After Trial Failure

THOMSON REUTERS
·
03 Dec 2024

Roivant Sciences' Kinevant Says Pulmonary Sarcoidosis Drug Candidate Fails to Meet Goals

MT Newswires Live
·
03 Dec 2024

Roivant Sciences Unit Kinevant Sciences' Lung Disease Drug Fails in Mid-Stage Study

Dow Jones
·
03 Dec 2024

BUZZ-Roivant falls as lung disease drug fails in mid-stage study

Reuters
·
03 Dec 2024

Roivant's lung disease drug fails mid-stage trial

Reuters
·
03 Dec 2024

Roivant Sciences Shares Down 2.6% Premarket After Co's Lung Disease Drug Fails to Meet Main Goal in Mid-Stage Study

THOMSON REUTERS
·
03 Dec 2024

Kinevant Sciences Announces Topline Results From Phase 2 Resolve-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

THOMSON REUTERS
·
03 Dec 2024

Roivant Announces Topline Results From Phase 2 Resolve-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

THOMSON REUTERS
·
03 Dec 2024

Roivant Sciences Ltd - Kinevant to Discontinue Namilumab Development for Sarcoidosis

THOMSON REUTERS
·
03 Dec 2024

Roivant Sciences Ltd - Namilumab Fails to Meet Primary Endpoint in Phase 2 Study

THOMSON REUTERS
·
03 Dec 2024

Roivant Sciences Ltd - Secondary Endpoints Also Fail to Show Treatment Benefit

THOMSON REUTERS
·
03 Dec 2024

Musk, Ramaswamy plan to lean on Supreme Court rulings to reduce federal agencies reach

Reuters
·
21 Nov 2024

JPMorgan’s ‘Analyst Focus List’ – growth, income, value, short ideas

seekingalpha
·
20 Nov 2024

Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution

Simply Wall St.
·
19 Nov 2024

Defense Stocks Don't Have to Fear Elon Musk, Pete Hegseth, and the $600 Hammer -- Barrons.com

Dow Jones
·
15 Nov 2024

Roivant Sciences Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Nov 2024

TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)

TIPRANKS
·
13 Nov 2024

Roivant Sciences Ltd reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
12 Nov 2024

Roivant Sciences' Fiscal Q2 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
12 Nov 2024